
51 - 200 employees
Founded 2013
🏥 Healthcare
🧬 Biotechnology
💊 Pharmaceuticals
💰 $217M Post-IPO Equity on 2020-08
Healthcare • Biotechnology • Pharmaceuticals
Adverum Biotechnologies is a company focused on developing gene therapies to treat debilitating ocular diseases. Their mission is to establish gene therapy as a new standard of care, particularly in treating conditions like wet age-related macular degeneration (wet AMD), which is a leading cause of blindness globally. The company is advancing their investigational gene therapy Ixo-vec, designed to provide a long-lasting treatment through a single in-office administration, which could replace the current standard of frequent and painful eye injections. By leveraging their proprietary adeno-associated virus (AAV) vector platform, Adverum aims to transform the standard of care, improve accessibility to treatment, and achieve significant societal impact by restoring vision and preventing blindness.
Selected: 🇺🇸 United States – Remote USA.
Selected: 🆕 Date Added.
🕒 August 5
Director leading HEOR evidence generation for Adverum’s gene therapy and ophthalmology portfolio. Shaping global product strategy, lifecycle planning, and cross-functional stakeholder decisions.
🏄 California – Remote
💵 $75 - $130 / hour
💰 $217M Post-IPO Equity on 2020-08
⏳ Contract/Temporary
🔴 Lead
👔 Director
🦅 H1B Visa Sponsor
👻 Ghost score 0%
🕒 August 5
Associate Director leading scientific communications and medical affairs for Adverum, an Eli Lilly-owned gene therapy company. Analyzing clinical data, guiding publications, and supporting ophthalmology-focused launch activities.
🏄 California – Remote
💵 $65 - $110 / hour
💰 $217M Post-IPO Equity on 2020-08
⏳ Contract/Temporary
🟠 Senior
👔 Director
🦅 H1B Visa Sponsor
👻 Ghost score 0%